Integrated Biopharma Valuation
| INBPDelisted Stock | USD 0.23 0.01 4.55% |
Integrated Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Integrated Biopharma from evaluating the firm fundamentals such as Current Valuation of 12.05 M, return on equity of 0.13, and Return On Asset of 0.0336 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage buying undervalued assets and selling overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Overvalued
Today
Please note that Integrated Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Integrated Biopharma is based on 3 months time horizon. Increasing Integrated Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Integrated Biopharma is useful when determining the fair value of the Integrated otc stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Integrated Biopharma. Since Integrated Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Integrated OTC Stock. However, Integrated Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.23 | Real 0.2 | Hype 0.23 |
The real value of Integrated OTC Stock, also known as its intrinsic value, is the underlying worth of Integrated Biopharma OTC Stock, which is reflected in its stock price. It is based on Integrated Biopharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Integrated Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integrated Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Integrated Biopharma helps investors to forecast how Integrated otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integrated Biopharma more accurately as focusing exclusively on Integrated Biopharma's fundamentals will not take into account other important factors: Integrated Biopharma Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Integrated Biopharma's current stock value. Our valuation model uses many indicators to compare Integrated Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integrated Biopharma competition to find correlations between indicators driving Integrated Biopharma's intrinsic value. More Info.Integrated Biopharma is rated third overall in price to earning category among related companies. It is rated second overall in price to book category among related companies fabricating about 0.22 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Integrated Biopharma is roughly 4.47 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Integrated Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Integrated Biopharma's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integrated Biopharma's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Integrated Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Integrated Biopharma and how it compares across the competition.
About Integrated Biopharma Valuation
The otc valuation mechanism determines the current worth of Integrated Biopharma on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Integrated Biopharma. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Integrated Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Integrated Biopharma's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Integrated Biopharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Integrated Biopharma. We calculate exposure to Integrated Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Integrated Biopharma's related companies.Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.
8 Steps to conduct Integrated Biopharma's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Integrated Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Integrated Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Integrated Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Integrated Biopharma's revenue streams: Identify Integrated Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Integrated Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Integrated Biopharma's growth potential: Evaluate Integrated Biopharma's management, business model, and growth potential.
- Determine Integrated Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Integrated Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Integrated Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Integrated Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.9 M | |
| Quarterly Earnings Growth Y O Y | -0.636 | |
| Retained Earnings | -32.3 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |